Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Clinical trial NCT07341867 · RECRUITING

Trial details

NCT number: NCT07341867
Sponsor: Andrew Hantel, MD
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma Triple Negative Breast Cancer Duffy Blood Group, Chemokine Receptor Gene Mutation Duffy Blood Group, Chemokine Receptor Gene C.-67T>C

Start date: 2026-07-30
Primary completion: 2028-03-31
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.